Skip to the content
Please enable JavaScript in your browser to complete this form.
Lung Ambition Alliance Advisory Board Meeting
Pre-meeting survey
1. Is lung cancer screening considered a priority in Hong Kong?
*
Yes, it is a top priority
Somewhat, but there are also other healthcare priorities to focus on
No, it is not a priority
2. Do you think there is sufficient evidence to start shaping the healthcare environment in Hong Kong for lung cancer screening?
*
Yes
No
Yes – please state the most important study to support lung cancer screening in Hong Kong :
*
No – please state what further evidence is required :
*
3. In your opinion, why is there a need for early lung cancer screening in Hong Kong? (Please select all that apply)
*
Reductions in lung cancer mortality
Opportunities to detect risk for other lung-related conditions such as COPD and CVD, and smoking cessation
Reduced burden on healthcare systems
Others
3. If Others, please specify :
*
4. In your experience, what are the barriers and unmet needs among patients in the uptake of lung cancer screening in Hong Kong? (Please select all that apply)
*
Lack of awareness
Financial concerns
Perceptions, fears and stigma
Access to screening centres
Others
4. If Others, please specify :
*
5. In your experience, what are the barriers and unmet needs among healthcare professionals in the uptake of lung cancer screening in Hong Kong? (Please select all that apply)
*
Lack of standardized screening protocols
Challenges in identifying eligible patients
Lack of local lung cancer screening studies
Skepticism and lack of education regarding the benefits and effectiveness of screening among the public
Managing incidental pulmonary nodules
Difficulty in influencing government healthcare policies
Lack of cost effectiveness analysis in lung cancer screening
Others
5. If Others, please specify :
*
6. What are the key short-term strategies for the next 3 years to aid successful implementation of early lung cancer screening in Hong Kong in the long run?
*
7. Please list the actions or initiatives that you think are the most important at this stage to help advance lung cancer screening framework in Hong Kong.
*
8. AstraZeneca prioritises lung cancer screening as a very important strategy in advancing lung cancer outcomes and reducing mortality among patients. We would like to invite you to be our steering committee member, and to advise and steer key initiatives in lung cancer screening in Hong Kong. The scope of work can be further discussed to suit the convenience of each committee member.
Do you agree to be a steering committee member and work with AstraZeneca in advancing lung cancer screening in Hong Kong?
*
8. AstraZeneca prioritises lung cancer screening as a very important strategy in advancing lung cancer outcomes and reducing mortality among patients. We would like to invite you to be our steering committee member, and to advise and steer key initiatives in lung cancer screening in Hong Kong. The scope of work can be further discussed to suit the convenience of each committee member. Do you agree to be a steering committee member and work with AstraZeneca in advancing lung cancer screening in Hong Kong?
*
a. Yes
b. No
Submit